ncbi.nlm.nih.gov/pmc/articl...
The role of prolactin in CRPC.
Clioquinol could be taken as a cream!
Conclusions
Terminal androgen-independent prostate is prolactin dependent, decreased zinc, ZIP1- deficient malignancy in which conditions that will increase zinc uptake and accumulation will exhibit cytotoxic/tumor suppressor effects.
Experimental studies demonstrate that the topical cutaneous application of 3% clioquinol cream will provide transdermal absorption of clioquinol into blood, which will result in mobile ZnCQ that is delivered to malignant sites, transports zinc into the ZIP-deficient malignant cells, and induces cytotoxic/tumor suppression effects. Treatment with the dopamine agonist, cabergoline, will decrease plasma prolactin level, thereby preventing prolactin-induced progression of androgen-independent malignancy.
FDA “Compassionate use” policies should permit clioquinol and cabergoline treatment of terminal androgen-independent cancer and without unnecessary delay.
And here a very interesting case: ncbi.nlm.nih.gov/pmc/articl...